The enantioselective installation of a methyl group onto a small molecule can result in the
significant modification of its biological properties. While hydroalkylation of olefins …

Sigma1 Receptor (S1R) is involved in oxidative stress, since its activation is triggered by
oxidative or endoplasmic reticulum stress. Since specific aquaporins (AQP), called …

In the early 2000s, the Sigma Receptor (SR) family was identified as potential “druggable”
target in cancer treatment. Indeed, high density of SRs was found in breast, lung, and …

Herein we report the synthesis, drug-likeness evaluation, and in vitro studies of new sigma
(σ) ligands based on arylalkenylaminic scaffold. For the most active olefin the corresponding …

The present work proposed a novel therapeutic platform with both neuroprotective and
neuroregenerative potential to be used in the treatment of spinal cord injury (SCI). A dual …

Our recent research efforts identified racemic RC‐33 as a potent and metabolically stable σ1
receptor agonist. Herein we describe the isolation of pure RC‐33 enantiomers by chiral …

The enantiomers of four chiral 3-aryl-substituted-γ-butyrolactones, key intermediates for the
preparation of compounds of pharmaceutical interest, were successfully isolated by …

The human Sigma1 receptor (S1R), which has been identified as a target with an important
role in neuropsychological disorders, was first crystallized 3 years ago. Since S1R structure …

Strong pharmacological evidences indicate that σ1 receptors are implicated in the
pathophysiology of all major CNS disorders. In the last years our research group has …

Injuries to the nervous system affect more than one billion people worldwide, and
dramatically impact on the patient's quality of life. The present work aimed to design and …